Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

AIMS: Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure (SBP),according to baseline SBP in Dapagliflozin and Prev...

全面介紹

Na minha lista:
書目詳細資料
發表在:Eur Heart J
Main Authors: Serenelli, Matteo, Böhm, Michael, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Solomon, Scott D, DeMets, David L, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Anand, Inder S, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Diez, Mirta, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E A, Verma, Subodh, Docherty, Kieran F, Jhund, Pardeep S, McMurray, John J V
格式: Artigo
語言:Inglês
出版: Oxford University Press 2020
主題:
Clinical Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7550197/
https://ncbi.nlm.nih.gov/pubmed/32820334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa496
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍